The chief scientific officer at REGENXBIO discussed RGX-202 and the ongoing clinical trial.
Olivier Danos, PhD
Advertisement
Articles by Olivier Danos, PhD
The chief scientific officer at REGENXBIO discussed multiple presentations given by the company at the 2023 ASGCT meeting.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
CGTLive®’s Weekly Rewind – October 24, 2025
2
Guess the Therapy Answer October 23, 2025
3
CARsgen’s CAR-T Satri-Cel Significantly Reduces CA19-9 Levels in Patients With Pancreatic Ductal Adenocarcinoma
4
